Cantor Fitzgerald Weighs in on PVLA FY2025 Earnings

Palvella Therapeutics (NASDAQ:PVLA) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Palvella Therapeutics in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will post earnings of ($1.60) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Palvella Therapeutics’ current full-year earnings is ($3.69) per share.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $38.00 price target on shares of Palvella Therapeutics in a research note on Friday, January 10th.

Palvella Therapeutics Stock Down 0.4 %

Shares of PVLA stock opened at $13.15 on Thursday. Palvella Therapeutics has a 52-week low of $6.20 and a 52-week high of $22.32.

Insiders Place Their Bets

In other Palvella Therapeutics news, Director George M. Jenkins purchased 4,000 shares of the stock in a transaction dated Wednesday, December 18th. The stock was purchased at an average price of $12.93 per share, with a total value of $51,720.00. Following the transaction, the director now owns 180,671 shares of the company’s stock, valued at approximately $2,336,076.03. This trade represents a 2.26 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 6.39% of the stock is currently owned by insiders.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.